Australia markets closed

Novartis AG (NVS)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
85.39+0.25 (+0.29%)
As of 11:46AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close85.14
Bid85.32 x 4000
Ask85.33 x 900
Day's range84.27 - 85.56
52-week range79.34 - 95.17
Avg. volume2,493,496
Market cap193.421B
Beta (5Y monthly)0.56
PE ratio (TTM)19.72
EPS (TTM)4.33
Earnings dateN/A
Forward dividend & yield3.20 (3.76%)
Ex-dividend date04 Mar 2021
1y target est101.40
  • Motley Fool

    1 Top Dividend Stock to Buy Right Now

    The pharmaceutical industry is an excellent place to look for dividend stocks. Since no one can predict illnesses in advance -- or the timing of the need for lifesaving medicines -- the demand for the drugs that pharma companies offer remains relatively constant regardless of economic conditions. Let's examine one pharma company that looks like an outstanding dividend stock to buy right now: Novartis (NYSE: NVS).

  • Motley Fool

    2 Cheap Dividend Stocks With Yields Above 3%

    For example, at their current share prices, both Novartis (NYSE: NVS) and Chevron (NYSE: CVX) yield more than 3%. If you buy shares of Novartis today, you'll collect around 3.7% just in dividend income at the current payout level. The pharmaceutical company has increased its annual dividend payments for 24 years in a row -- and a hike this year would make it a Dividend Aristocrat.

  • GlobeNewswire

    Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I am delighted to welcome Cintia to our leadership team. She brings extensive commercial experience, including in cell and gene therapy, that will be key as we prepare to submit our first BLA for afami-cel this year, and buil